Selinexor combination therapy in MDS/MPN overlap syndromes
Current understanding
Selinexor (XPO1 inhibitor) combined with either azacitidine or ruxolitinib is being prospectively investigated in MDS/MPN overlap syndromes (CMML, MDS/MPN-U, aCML, MDS/MPN-RS-T), a population with few approved options. A multicenter prospective study reported a 60% overall response rate with manageable toxicity (trial-early evidence), supporting further development in this underserved overlap population.
Evidence log
Open questions
Related
Contributing findings
Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.
01-jul-2026
novelty 3
per-area 3
introduces